Medlab Clinical Limited (MDC) 2019年年度报告「ASX」.pdf

1、NanoCelleTMTechnology ProbioticsNutraceuticalsCopyright Medlab Clinical Ltd 2019MEDLAB CLINICAL LIMITED(ABN 51 169 149 071)ANNUAL REPORTFOR THE YEAR ENDED 30 JUNE 2019JUN2017Ethics granted for NanaBis and NanaBidial cannabis trialsSEPT2017Granted 20 Year Australian Patent for its anti-depression pro

2、duct(NRGBiotic)JAN2018Granted licences to sell or supply Cannabis in AustraliaJAN2018Completes over-subscribed placement raising$24m before costsMAY2018NanaBis trial at Royal North Shore Hospital commencesJUL2018Recruitment commences for Phase 2a NRGBiotic/Depression TrialAUG2018Ethics granted for n

3、ew oncology trial(Mucositis)SEPT2018Medlab starts talks with the FDA and EMA for NanaBis Drug RegistrationSEPT2018Granted a licence to export CannabisOCT2018Successful completion of Stage 1 of NanaBis trial at Royal North Shore HospitalJUL2012Sold BioCeuticalsto Blackmores(ASX:BKL)for$43M.BioCeutica

4、ls was Australias leading Practitioner brand.OCT2012Medlab secures Alexandria premiseAUG2013Govt certification for Alexandria labJUL2015Medlab admitted to ASX(ASX:MDC)raising$6.2m before costsJUL2015Granted a Cannabis research licenceJUL2016Completes Rights Issue raising$5.4m before costsAUG2016Medl

5、ab and Aphria Inc executes Cannabis supply agreementAUG2016Completes Phase 1 NRGBiotic/Depression TrialNOV2016Granted licence for the import of CannabisMAR2017Ethics granted for Phase 2a NRGBIOTIC/Depression TrialDEC2018Medlab expands into EuropeJAN2019Successful completion of NanoStat trial(Atorvas

6、tatin)MAR2019Medlab expands into AU banner pharmacyMAR2019Heads of Agreement for NanaBis executed with Pharmascience IncAPR2019Medlab achieves monthly revenue in excess of$1m for the first timeMAY2019Heads of Agreement for NanaBis executed with Mega LifesciencesJUN2019Ethics granted for second NanaB